IZERVAY

Iveric Bio, under Astellas Company, is a trailblazing biopharmaceutical force driven by the pursuit of innovative treatments for retinal diseases, notably various stages of age-related macular degeneration (AMD). Collaborating with Brandsymbol, they endeavored to establish a robust global brand identity for their promising drug candidate, avacincaptad pegol.

The relentless progression of geographic atrophy (GA), an advanced AMD form, casts a shadow over countless lives, with a prominent impact on quality of life. Over 5.5 million global sufferers, including 1.5 million in the US, face a stark lack of viable treatment options, relying on supportive care. Iveric Bio and Brandsymbol collaborated to explore brand strategies for avacincaptad pegol, a breakthrough complement C5 inhibitor targeting vision preservation. This investigational agent takes aim at the cleavage of complement protein C5 and its fragments, C5a and C5b, instilling a sense of optimism for countless individuals.

On August 8, 2023, Iveric Bio received FDA approval for Izervay™. The name seamlessly blends “eye” and “preservation,” encapsulating the core mission of safeguarding patients’ eyesight. This strategic approach seamlessly extended into the design, yielding a logo reminiscent of a hopeful sunrise. The choice of friendly fonts and calming colors reinforces the message of inspiration and optimism. By positioning Izervay™as a steadfast ally in preserving sight for the 5.5 million plus affected by this condition, Brandsymbol’s strategic branding embodies Iveric Bio’s commitment to innovation and patient welfare on a global scale.